Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Latest Information Update: 02 Apr 2024
At a glance
- Drugs Belantamab mafodotin (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 17 May 2023 Status changed from suspended to active, no longer recruiting.
- 28 Mar 2023 Planned number of patients changed from 12 to 76.